Price History
Feb 9, 2026 — Aug 17, 2026Investment Snapshot
- Trading 300% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 5.7% — below-average profitability
- Revenue declining 5% annually
Alkermes plc - Ordinary Shares (ALKS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $8.2 billion . Key value metrics: P/E ratio 79.2, P/B ratio 4.55, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Alkermes plc - Ordinary Shares — Fundamental Analysis Summary
Alkermes plc - Ordinary Shares (ALKS) is currently trading 300% above its Graham Number of $12.26, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 79.2x.
On financial health, ALKS shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 5.7% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.84.
StockPik's composite Value Score for ALKS is 44/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ALKS reports a high gross margin of 84.4% (sector average: 37.4%) and a modest operating margin of 9.1%.
ALKS shows revenue declining at 5% year-over-year, with earnings declining at 34%.